Literature DB >> 14600190

Contemporary management of chronic obstructive pulmonary disease: clinical applications.

S F Paul Man1, Finlay A McAlister, Nick R Anthonisen, Don D Sin.   

Abstract

The presentation of chronic obstructive pulmonary disease (COPD) usually is insidious, and many patients are undiagnosed until the disease is far advanced. Therefore, the early use of spirometry is recommended for anyone who is suspected to have COPD. In the early stages of the disease, the patient is only mildly symptomatic (cough and sputum production). As COPD becomes more advanced, functional impairment in the form of chronic dyspnea occurs and acute exacerbations of symptoms become more frequent, contributing to overall morbidity and mortality. The single most important known causative factor of COPD is cigarette smoking. Smoking cessation remains, therefore, the mainstay of COPD therapy. In patients with advanced disease, symptomatic treatment with the regular use of either short- or long-acting sympathomimetic and/or anticholinergic bronchodilators, singly or in combination, should be added to smoking cessation and influenza and pneumococcal vaccination therapies. An inhaled corticosteroid, either alone or more commonly in combination with a long-acting bronchodilator, can further reduce exacerbations and improve the health status of these patients. Furthermore, patients with severe COPD, particularly those who are debilitated, should be considered for pulmonary rehabilitation because these programs have been proven useful in maintaining, or in some cases improving, health status for these patients. Finally, correction of resting arterial hypoxemia with oxygen therapy for more than 15 h/d prolongs survival of COPD patients for those with a resting PaO2 lower than 55 to 60 mm Hg.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14600190     DOI: 10.1001/jama.290.17.2313

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  8 in total

Review 1.  Epidemiology and management of common pulmonary diseases in older persons.

Authors:  Kathleen M Akgün; Kristina Crothers; Margaret Pisani
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-02-15       Impact factor: 6.053

2.  Comparison of lidocaine and bronchodilator inhalation treatments for cough suppression in patients with chronic obstructive pulmonary disease.

Authors:  C-F Chong; C-C Chen; H-P Ma; Y-C Wu; Y-C Chen; T-L Wang
Journal:  Emerg Med J       Date:  2005-06       Impact factor: 2.740

3.  Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial.

Authors:  Donald P Tashkin; Dennis E Doherty; Edward Kerwin; Carlos E Matiz-Bueno; Barbara Knorr; Tulin Shekar; Sibabrata Banerjee; Heribert Staudinger
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-02-03

Review 4.  Combining scores from different patient reported outcome measures in meta-analyses: when is it justified?

Authors:  Milo A Puhan; Irene Soesilo; Gordon H Guyatt; Holger J Schünemann
Journal:  Health Qual Life Outcomes       Date:  2006-12-07       Impact factor: 3.186

5.  The therapeutic effects of qigong in patients with chronic obstructive pulmonary disease in the stable stage: a meta-analysis.

Authors:  Hongxuan Tong; Yihua Liu; Yutian Zhu; Boli Zhang; Jingqing Hu
Journal:  BMC Complement Altern Med       Date:  2019-09-04       Impact factor: 3.659

Review 6.  Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety.

Authors:  Andrea Rossi; Sonia Khirani; Mario Cazzola
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

Review 7.  Treatment of mild chronic obstructive pulmonary disease.

Authors:  Alex Chee; Don D Sin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

Review 8.  Chinese Herbal Medicine and Salmeterol and Fluticasone Propionate for Chronic Obstructive Pulmonary Disease: Systematic Review and Network Meta-Analysis.

Authors:  Vincent C H Chung; Xinyin Wu; Polly H X Ma; Robin S T Ho; Simon K Poon; David S Hui; Samuel Y S Wong; Justin C Y Wu
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.